An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease
Phase of Trial: Phase IV
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Atorvastatin (Primary) ; Vitamin E
- Indications Hypercholesterolaemia; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 02 Feb 2016 Planned End Date changed from 1 Dec 2013 to 1 Dec 2016, as reported by ClinicalTrials.gov.
- 17 Jul 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.